ArticleCommunications biology2026
Inhibiting glucocorticoid receptors enhances adult spinal cord neural stem cell activity and improves outcomes in spinal cord injury.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spinal cord injury (SCI) microenvironment undergoes significant biochemical changes that influence the behavior of endogenous neural stem/progenitor cells (NSPCs), including elevated glucocorticoid levels. Here, we investigate the effects of glucocorticoids on NSPCs in the adult mouse spinal cord. Adult spinal cord NSPCs express glucocorticoid receptors but not mineralocorticoid receptors. Glucocorticoid exposure significantly inhibits NSPC proliferation, neurosphere formation, and differentiation through glucocorticoid receptor activation. In a traumatic SCI mouse model, treatment with the glucocorticoid receptor inhibitor CORT125281 improves motor function and increases the number of NSPCs at the injury site. Flow cytometry and RNA sequencing analyses show that glucocorticoids induce NSPC G0/G1 cell-cycle arrest through activation of the p53 signaling pathway, accompanied by increased expression of the cell-cycle regulators p15, p18, and p27. These findings suggest that glucocorticoid elevation after SCI suppresses endogenous NSPC proliferation via glucocorticoid receptor activation, and targeting this pathway may represent a potential therapeutic strategy to enhance recovery after SCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.